Jupiter Neurosciences, Inc. announced that Annika Sörenstam, a Hall of Fame golfer and leading figure in women's golf, has become the first brand ambassador for their new longevity supplement line, ...

Jupiter Neurosciences, Inc. has announced the launch of Nugevia™ PWR, a daily mitochondrial health supplement designed to enhance cellular energy, endurance, and recovery. This product is part of ...

While being a biotech company can be difficult, it is not impossible. Just look at Jupiter Neurosciences Inc. JUNS, a clinical-stage pharmaceutical company, for evidence. The company, which is ...

Jupiter, Florida, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (JUNS), a clinical-stage pharmaceutical company developing JOTROL ™, a patented resveratrol-based therapeutic platform ...

Jupiter Neurosciences Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company developing JOTROL™ – an enhanced orally administered resveratrol formulation known for its antioxidant and ...

JUPITER, FL, UNITED STATES, January 28, 2026 /EINPresswire.com/ — Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage ...

With our Phase IIa program underway and defined milestones in front of us, we look forward to engaging with investors and potential partners at BIO.” — Christer Rosén, Chairman and Chief Executive ...

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Jupiter Neurosciences, Inc.

Detailed price information for Jupiter Neurosciences Inc (JUNS-Q) from The Globe and Mail including charting and trades.

Cash Runway Extended to Finance the Parkinson’s Program; Debt Paydown Improves Shareholder Equity Position Jupiter, FL, May 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ...